Feature | Longevity and geroscience | BioPharma APAC

The closed front door

Start with the fact that shapes everything else. There is no jurisdiction on earth in which aging is an approvable indication. The position is clearest in the United States, where the agency's non-recognition of aging as an indication has been the field's defining constraint for a decade, and where, as of mid-2026, no epigenetic clock has been accepted as a surrogate endpoint. Nothing in the published positions of Japan's PMDA, China's NMPA, Korea's MFDS, Singapore's HSA, India's CDSCO or Australia's TGA departs from that. A sponsor cannot file for aging. It can only file for something aging causes.

Now put that against the demography. Japan, South Korea, Taiwan and Singapore have already crossed into super-aged classification, Thailand and Malaysia are close behind, and by 2030 one in four people in Asia will be over 60. There is no other region where the gap between demand for an intervention and the legal availability of one is this wide, this rich, or this politically urgent.

When demand of that size meets a closed front door, the traffic does not stop. It goes around. In Asia-Pacific it has gone around by three distinct routes, and the difference between them is not scientific sophistication but where the evidence obligation sits.

The first route sells the intervention as a medical service under a national framework that lawfully permits unapproved cell-based therapy. The second borrows an adjacent indication that a regulator will already accept, and develops the asset conventionally against it. The third tries to qualify a biomarker, so that aging becomes measurable, and therefore eventually filable.

The finding that runs through what follows is an uncomfortable one for a region that likes to describe itself as a longevity leader. Asia-Pacific leads the world decisively on route one. It is a junior partner on route three. And it owns the underlying science for route two more completely than any other region, without having converted that ownership into a single approved product or a single seat of proportionate influence at the table where the global standards are being written.

Route one: sell it as a service

Japan built the door, and it built it more than a decade ago.

The Act on the Safety of Regenerative Medicine, promulgated in 2013 and implemented on 25 November 2014, does something no Western framework does. It regulates the provision of regenerative medicine using cell products that have not been approved under the Pharmaceuticals and Medical Devices Act, allowing them to be provided either as non-commercial clinical research or as out-of-pocket therapy at a physician's discretion, subject to a risk classification and review by a Certified Committee for Regenerative Medicine.

The scale that framework has reached is the single most underreported number in the longevity conversation. Since the Act came into force, more than 1,000 regenerative medicine provision plans have been approved, and more than 10,000 patients receive treatment under it each year. There is no comparable lawful market anywhere else.

The Act was amended by Act No. 51 of 14 June 2024, with the amended cabinet order promulgated on 6 December 2024 and the amended ministerial ordinance on 28 February 2025, both taking effect with the amended Act on 31 May 2025. The amendment brings in vivo gene therapy and related technologies into scope as the highest-risk class, requires conflict-of-interest management, requires Certified Committees to conduct a specific assessment of the scientific validity of each provision plan, and creates on-site inspection powers and grounds for disqualifying a committee.

Read that amendment carefully and you can see what Japan is actually worried about. The new obligations are about the integrity of the review, not about the strength of the claim. A provision plan must now survive a scientific-validity assessment by a committee that can be inspected and disqualified. It still does not have to demonstrate efficacy in the sense a marketing authorisation would require. Safety and process integrity are regulated. Outcome is not.

That distinction is the commercial engine of the route. A clinic operating lawfully under the Act carries a compliance burden, a documentation burden and now an inspection risk, but not a registrational one. Anti-aging and vitality optimisation are the highest-margin uses that fit inside a framework originally designed for orthopaedic, ophthalmic and neurological cell therapy. The door was built for one thing and a market walked through it.

Korea watched this happen for a decade and has now built its own door, explicitly to keep its patients at home.

The Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products, Act No. 16556 of 27 August 2019, took effect in 2020 with a narrow design: advanced regenerative medicine could be administered only inside approved clinical research protocols, and patients could not be charged. The result was a framework that barely moved. As of November 2025, only 50 clinical research plans had been approved under it, most of them cell-based therapies delivered in tertiary hospitals.

The amendment of 20 February 2024, in force from 21 February 2025, creates a new legal category of advanced regenerative medicine treatment that sits outside the clinical research system. Institutions can provide therapies as treatment rather than as research, subject to ethics committee approval and safety standards; treatment plans must state purpose, target population, safety and efficacy evidence and cost calculations; the minister gains site inspection authority; and adverse reaction definitions and safety investigation scope are broadened in subordinate regulation.

There is a live disagreement in the professional literature about how far eligibility now extends. Some advisories describe the amendment as lifting the previous restriction to severe, rare and incurable conditions so that patients with mild or common conditions can receive treatment. Ministry communications around commencement have continued to emphasise conditions that are serious, rare or incurable, or that lack an approved alternative. The distinction is not academic, because it determines whether an aging-related complaint can be treated as a qualifying condition at all. This is flagged in the verification note as an open item requiring confirmation against the Presidential Decree text.

Singapore has not built a door and has not decided whether to. Phase 2 licensing under the Healthcare Services Act, expected across 2026 and 2027, will determine whether longevity clinics are classified as medical services or as wellness services. That single classification decision carries more consequence for the regional market than any therapeutic result likely to be published in the same window. A medical classification imports clinical governance, advertising restrictions, practitioner accountability and eventually payer scrutiny. A wellness classification leaves a fast-growing diagnostic and infusion sector regulated broadly as a spa.

Meanwhile the market is being priced without waiting for the answer. A single hyperbaric oxygen session at a private Singapore wellness clinic ran between SGD 250 and SGD 400 as of mid-2026, red light therapy packages started around SGD 120 a session, and cryotherapy in upscale Bangkok centres ran roughly THB 2,500 to THB 4,000. Hospitality is moving in alongside: METT Singapore signed a partnership in October 2025 to bring a European anti-aging clinic brand into a hotel property.

The rest of the region occupies the space between these positions, and the variation is instructive. China regulates cell therapy through a dual track in which products developed for marketing sit with the NMPA while institution-led clinical research sits with the health commission, an arrangement that permits a great deal of hospital-based activity without producing registrational data. Thailand and Malaysia have become destination markets on the strength of cost and accessibility rather than on the strength of a distinctive legal framework, which places them in the weakest position of all: they carry the reputational exposure of the category without the inspection infrastructure that Japan has built around it. Australia sits at the opposite pole, having tightened its position on autologous cell therapy exemptions rather than loosened it, with the practical result that Australian patients travel and Australian sponsors develop conventionally.

Set those five positions side by side and a pattern emerges that has nothing to do with science. The jurisdictions with the most permissive provision frameworks are the ones with the most acute demographic pressure and the strongest domestic regenerative medicine industrial policy. Japan and Korea did not accidentally create the world's largest lawful market for unapproved cell therapy. They created a domestic industry runway, and longevity turned out to be the demand that filled it.

For a pharmaceutical audience the significance of route one is not that it is disreputable. Much of it is entirely lawful, some of it is delivered under stricter traceability than an equivalent Western clinic would face, and Japan's inspection powers are real. The significance is that route one is establishing the reference price, the patient expectation and the belief system for an entire category, years before a single approved gerotherapeutic reaches the region. Whoever eventually arrives with a registered product will be selling into a market that has already been taught what longevity medicine costs and what it feels like to buy.

 Route two: borrow an indication

If aging cannot be filed, something adjacent to it can. The available lanes are well known: sarcopenia and muscle health, frailty and intrinsic capacity, fibrotic disease, chronic kidney disease, immunosenescence, and several ophthalmic conditions in which age is the dominant risk factor.

Asia-Pacific's position in this route is genuinely distinctive, and almost entirely unmonetised.

The Asian Working Group for Sarcopenia has done something no other regional body in aging medicine has managed. Its 2014 consensus, revised in 2019, established diagnostic criteria and cut-off values calibrated to Asian body composition rather than imported from European cohorts, and those criteria became the operational definition across most of the region's research and much of its clinical practice. The 2025 consensus update, published in Nature Aging in November 2025, goes considerably further. It reframes sarcopenia from a disease diagnosis into a life-course muscle health framework, extends diagnosis to middle-aged adults between 50 and 64 with validated thresholds, simplifies the diagnostic algorithm to concurrent low muscle mass and low strength with physical performance repositioned as an outcome measure rather than a severity grade, and hooks case-finding into the World Health Organization's Integrated Care for Older People pathway.

Behind it sits pooled cohort work of a kind the field rarely produces, including multinational normative muscle health metrics drawn from eight cohorts across Japan, Malaysia and Taiwan.

This is the most consequential contribution Asia-Pacific has made to aging medicine, and it is a diagnostic framework rather than a drug. That matters more than it sounds, because in a category with no approvable indication, the endpoint is the asset. Whoever's criteria a regulator adopts determines who is eligible for a trial, what counts as a response, and which comparator a new agent must beat.

Which makes the composition of the global process worth stating plainly. The Global Leadership Initiative in Sarcopenia, working since 2021 towards an international definition, has a steering committee of 22 members, of whom four are from Asia. The region that produced the criteria most widely used across Asian populations holds under a fifth of the seats where the global replacement is being drafted. Commentary from within the Korean geriatrics community has been notably direct about this, framing it as a failure of regional scientific assertiveness rather than as exclusion.

The same argument applies with more force to intrinsic capacity, the composite of cognition, sensory function, locomotion, vitality and psychological state that the World Health Organization placed at the centre of its Integrated Care for Older People approach in 2017 and updated in 2024. Intrinsic capacity is the closest thing in current clinical practice to a measurable, multi-domain construct of healthy aging that a health system already collects, and the associational work linking it to sarcopenia is being done substantially in Asian populations, including outpatient cohorts in India and large longitudinal samples in China. India's position here is worth flagging separately, because it is the region's largest source of aging-cohort data and its smallest presence in aging therapeutics, and CDSCO has published nothing that would tell a sponsor how a frailty or intrinsic-capacity endpoint would be treated in an Indian filing.

The commercial risk is concrete. If a global definition is settled with Asian cohorts underweighted, sponsors running regional trials will enrol to thresholds that misclassify the patients in front of them, and the region's own epidemiological work becomes supporting literature for somebody else's label.

The pipeline picture reinforces the asymmetry. Senolytic small molecules accounted for the largest share of longevity market revenue in 2025 on the strength of relative clinical maturity, and the visible programmes are overwhelmingly North American. Unity Biotechnology, the first-generation senolytics company, reported encouraging Phase 2b results for UBX1325 in diabetic macular edema in March 2025 and subsequently wound down after clinical failure, having raised around USD 200 million through Series C. Cambrian Bio secured a USD 23 million platform extension in January 2026 to widen an incubated portfolio spanning oncology, obesity-linked disease and autoimmune conditions. Rubedo Life Sciences has been positioning a precision senolytic into clinical entry.

Asia-Pacific's most visible presence in the same conversation runs through Insilico Medicine, whose lead clinical asset emerged from aging-biology target selection and is being developed against fibrosis, and whose founder headlined the keynote programme at BIO Asia-Taiwan in July 2026. That is a real regional contribution, though it belongs to a different argument about discovery platforms, audited separately in this title, and it should not be made to carry the weight of an entire region's geroscience pipeline on its own.

The institutional base is thickening. China launched the Sirio Institute for Anti-Aging in February 2025 with a remit spanning cellular, gut, muscle and reproductive health. In January 2025 Japan's Renascience signed a joint research agreement on aging with the director of the Potocsnak Longevity Institute at Northwestern University and announced plans for a branch at the Tohoku University Renascience Open Innovation Lab.

What is largely missing is the middle. Between the epidemiology, which is excellent, and the institutes, which are new, there is very little Asia-Pacific-originated therapeutic development running against a borrowed aging-adjacent indication with a disclosed regulatory strategy. The reason is not mysterious. A borrowed indication requires a full development programme at full cost against an endpoint regulators still regard as soft. Route one produces revenue inside a quarter. 

Route three: qualify the biomarker

The third route attacks the constraint directly. If a biomarker of biological aging could be formally qualified as a surrogate endpoint, the economics of the entire field change: dose-finding studies become feasible, candidate gerotherapeutics can be screened in months instead of decades, and sponsors escape the multi-year, multi-disease composite designs that made trials like TAME so difficult to finance.

The candidate biomarkers are familiar. DNA-methylation clocks including Horvath, GrimAge, PhenoAge and DunedinPACE; plasma proteomic signatures; transcriptomic clocks; inflammatory and immune-aging panels. None of them is a qualified surrogate endpoint in any jurisdiction. Advocacy for qualification has been building steadily, and the venue everyone watches is the FDA's biomarker qualification pathway.

There is a reasonable argument that an Asia-Pacific authority should move first, and it is not being made loudly enough. The region has the population structures that make the question urgent, national biobank and cohort infrastructure in Japan, Korea, Singapore and Taiwan, health systems with an explicit policy commitment to compressing morbidity rather than extending lifespan, and, in Japan and Singapore, regulators with a demonstrated appetite for building novel pathways ahead of international consensus. No Asia-Pacific sponsor or authority has filed a qualification package.

What is happening instead is partnership, and the shape of it is telling. Life Biosciences, whose partial epigenetic reprogramming platform received FDA clearance for its ER-100 programme in January 2026 and which dosed its first patient later that year in a Phase 1 trial covering glaucoma and non-arteritic anterior ischemic optic neuropathy, is working with SingHealth's clinical network on translational research. The pattern repeats across the region: platform and regulatory strategy originate in the United States, validation cohorts and clinical networks come from Asia.

That is a good arrangement for an Asian health system, which acquires capability and data. It is a weaker one for Asian sponsors, because the qualification dossier, the regulatory precedent and the resulting standard belong to whoever files.

The capital flows confirm the same asymmetry from the other direction. Global anti-aging biotech funding reached USD 3.74 billion in the first quarter of 2026, up 56 per cent year on year. Yet biological-age diagnostics remain conspicuously underfunded relative to their prominence in the narrative, with investors appearing to treat biomarkers as enabling infrastructure rather than as the point of value capture. The single thing that would unlock the category is the thing the market is least willing to pay for.

 Nobody is the payer

None of the three routes has a payer behind it, and that is not an accident of timing.

Route one is designed to be cash-pay. Japan's framework exists precisely because these are provisions outside the approval and reimbursement system. Korea's amendment requires cost calculations inside the treatment plan because the treatments are charged for. Singapore's classification question is a payer question wearing a licensing costume: medical classification pulls services towards insurer and MediSave scrutiny, wellness classification leaves them outside the health financing conversation entirely. It is not surprising that the wellness and hospitality sector, rather than the health system, is currently capturing most of the spending in a market sized in the trillions.

Routes two and three face a harder version of the same problem. Consider what a successful gerotherapeutic actually does to a health budget. If an agent delays the onset of five age-related conditions by three years each, the saving appears across five separate budget lines, over a horizon longer than any electoral cycle, while the cost lands immediately in the pharmaceutical line. No Asia-Pacific payer currently operates a health technology assessment method that can capture value distributed that way. Japan's cost-effectiveness assessment framework, Korea's positive list and risk-sharing arrangements, Taiwan's global budget, Singapore's Agency for Care Effectiveness guidance and China's volume-based procurement machinery were all built to price treatments against comparators within an indication. A gerotherapeutic has no comparator and, formally, no indication.

There is one financing route that does not depend on a public payer changing its method, and it is being underexplored. Private health insurers and large employers in Japan, Korea, Singapore and Hong Kong carry concentrated exposure to exactly the morbidity that a gerotherapeutic would defer, and they operate on horizons closer to a decade than to a budget cycle. An insurer that could underwrite a delay in functional decline has a commercial reason to fund the evidence that a health ministry does not. Nothing in the current landscape suggests that conversation has moved beyond wellness benefits and screening packages, but it is the most plausible source of non-dilutive capital for a route two or route three programme in the region, and it does not require a regulator to change its position first.

The result is a structural inversion that should worry anyone building in this space. Super-aged health systems are, by construction, financing the consequences of aging at enormous scale while having no mechanism to finance its prevention. The demographic pressure that creates the demand is the same pressure that makes the budget unable to accommodate the answer.

 What would change the picture

Three developments would move this from a services market to a therapeutics market, and each is observable rather than speculative.

The first is a published regulatory position from an Asia-Pacific authority on aging-adjacent endpoints, even in draft. The nearest observable decision point is Singapore's Healthcare Services Act Phase 2 classification, which will reveal whether a serious regulator is willing to treat longevity provision as medicine. The second is an Asia-Pacific sponsor or academic consortium filing a biomarker qualification package rather than contributing cohorts to somebody else's. The third is the Asian Working Group for Sarcopenia framework carrying into the global definition with representation proportionate to the populations it was built from, so that the endpoint the region eventually runs trials against fits the patients the region actually has.

Until at least one of those happens, the pattern holds. Asia-Pacific will continue to lead the world in delivering longevity interventions and to follow it in proving them, and the price of a longevity intervention across the region will keep being set in clinics rather than in trials.

That is not a scandal, and framing it as one misses the mechanism. It is a market behaving rationally in the absence of a regulatory pathway, inside legal frameworks that were deliberately built to permit exactly this. The question it leaves for anyone developing a gerotherapeutic for this region is commercial rather than ethical. By the time an approved product arrives, who will the patient already be paying, and what will they already believe they are getting?

what is being sold, and what the evidence supports

Provision of unapproved cell-based therapy under Japan's Act on the Safety of Regenerative Medicine is lawful and subject to safety and, since 31 May 2025, scientific-validity review. It is not evidence of efficacy for aging-related claims, and the Act does not require any.

Advanced regenerative medicine treatment under Korea's amended Act requires safety and efficacy evidence within the treatment plan and disclosure of cost. It sits outside the marketing authorisation system and does not constitute approval.

Biological age reports generated from epigenetic, proteomic or immune panels are not qualified surrogate endpoints in any jurisdiction. A change in a reported biological age has no established regulatory meaning.

Adjunctive modalities widely sold in regional longevity clinics, including hyperbaric oxygen, red light therapy and cryotherapy, are offered for aging indications largely outside the evidentiary standard that would be required for a therapeutic claim. Prices cited in this feature are dated to mid-2026 and are not comparative endorsements.

arcilla.fran@biopharmaapac.com